A company with …
a novel, simple but sophisticated and highly innovative, peptide approach to immuno-oncology. P28R as a drug concept is extraordinary. It is a First-In-Class, being the first and only immunomodulatory peptide in the IO field.
CanImGuide has discovered, and thoroughly demonstrated, that a previously unknown immunosuppressive peptide named P3028 is formed in malignant tumors through the breakdown of albumin. This intra-tumoral albumin peptide binds to the LFA-1 receptor (an integrin with a key role in immune cell functioning) and is thereby blocking an important component in the natural immune defense that normally contributes to kill cancer cells.